Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.42 |
| ▸ | CA1 | P00915 | 12/20 | 0.42 |
| ▸ | CA9 | Q16790 | 10/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598408 | 0.80 | CA1 (0.40) | CA2CA1CA9CA12CA6 | |
| SCHEMBL8679535 | 0.80 | CA2 (0.44) | CA2CA1CA9CA12CA6 | |
| SCHEMBL6063207 | 0.76 | KDM4E (0.41) | CA2CA1CA9CA12CA6 | |
| SCHEMBL4564552 | 0.75 | CA2 (0.39) | CA2CA1CA9CA12CA6 | |
| SCHEMBL7166967 | 0.73 | CA1 (0.38) | CA2CA1CA9CA12CA6 | |
| SCHEMBL8428528 | 0.72 | CA2 (0.47) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1106519 | 0.71 | CA1 (0.53) | CA2CA1CA9CA12CA6 | |
| SCHEMBL21826752 | 0.71 | CA2 (0.50) | CA2CA1CA9CA12CA6 | |
| SCHEMBL29469924 | 0.71 | CA2 (0.50) | CA2CA1CA9CA12CA6 | |
| SCHEMBL29933194 | 0.71 | CA2 (0.50) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | CA2 2364/4885CA1 4536/4885CA9 3212/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | CA2 2458/4885CA1 4583/4885CA9 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.